Prognostic Factors in Metastatic Melanoma: A Pooled Analysis of Eastern Cooperative Oncology Group Trials
- 15 November 2000
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (22), 3782-3793
- https://doi.org/10.1200/jco.2000.18.22.3782
Abstract
PURPOSE: To identify factors that are prognostic for survival in patients with metastatic melanoma treated in eight Eastern Cooperative Oncology Group (ECOG) trials conducted over the past 25 years...Keywords
This publication has 19 references indexed in Scilit:
- High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993Journal of Clinical Oncology, 1999
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.Journal of Clinical Oncology, 1998
- Prognostic factors for survival of patients treated systemically for disseminated melanoma.Journal of Clinical Oncology, 1998
- Prognostic Factors in Metastatic Malignant MelanomaOncology, 1997
- Prolonged survival of 2 years or longer for patients with disseminated melanomaCancer, 1997
- Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysisCancer, 1993
- Prognostic factors in metastatic melanomaCancer, 1993
- Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma IV. Late results after complete response to chemotherapy (central oncology group protocols 7130, 7131, and 7131A)Cancer, 1984
- Prognostic factors in metastatic malignant melanoma. The southeastern cancer study group experienceCancer, 1982